2030 – Can TGF- β be a valuable marker for psychosis?

Role of cytokines has been widely investigated in schizophrenia. Previous data suggest that TGF- β pathways can be hyperactive in schizophrenia. Serum levels of TGF- β showed to be significantly increased in psychotic patients with first episode psychosis and schizophrenia in relapse. As a part of r...

Full description

Saved in:
Bibliographic Details
Published inEuropean psychiatry Vol. 28; no. S1; p. 1
Main Authors Borovcanin, M., Djukic Dejanovic, S., Radosavljevic, G., Jovanovic, I., Stefanovic, V., Arsenijevic, N., Lukic, M.L.
Format Journal Article
LanguageEnglish
Published Elsevier SAS 2013
Subjects
Online AccessGet full text
ISSN0924-9338
1778-3585
DOI10.1016/S0924-9338(13)76960-8

Cover

Abstract Role of cytokines has been widely investigated in schizophrenia. Previous data suggest that TGF- β pathways can be hyperactive in schizophrenia. Serum levels of TGF- β showed to be significantly increased in psychotic patients with first episode psychosis and schizophrenia in relapse. As a part of recently publish research, we try to establish if TGF- β can be a valuable marker for psychosis. We investigated psychotic patients, with first episode psychosis and schizophrenia in relapse (133 subjects) and healthy controls (36 subjects). Diagnoses were established using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). The psychopathological status of psychotic patients was assessed by trained physicians using Positive and Negative Syndrome Scale (PANSS). Serum level of cytokine was measured using sensitive enzyme-linked immunosorbent assay (ELISA). Binary logistic regression showed that increased level of TGF- β strongly correlated with presence of psychosis (OR 1.068 (1.015-1.123)). Analysis showed that TGF- β can be a valuable marker for psychosis (area=0.775, p<0.0005). The optimal cutoff value estimated for TGF- β that allows the discrimination of psychotic from non psychotic patients was 22pg/ml. For this cut-off we got sensitivity 70.4% and specificity 80.6%, i.e. this concentration of 22pg/ml TGF- β could have prognostic value. We envisage the possible role of TGF- β as a biomarker in preceding schizophrenia and showed that increased level of TGF- β enhanced the risk for psychosis. According to our results, TGF- β could be a valuable marker for schizophrenia.
AbstractList Role of cytokines has been widely investigated in schizophrenia. Previous data suggest that TGF- β pathways can be hyperactive in schizophrenia. Serum levels of TGF- β showed to be significantly increased in psychotic patients with first episode psychosis and schizophrenia in relapse. As a part of recently publish research, we try to establish if TGF- β can be a valuable marker for psychosis. We investigated psychotic patients, with first episode psychosis and schizophrenia in relapse (133 subjects) and healthy controls (36 subjects). Diagnoses were established using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). The psychopathological status of psychotic patients was assessed by trained physicians using Positive and Negative Syndrome Scale (PANSS). Serum level of cytokine was measured using sensitive enzyme-linked immunosorbent assay (ELISA). Binary logistic regression showed that increased level of TGF- β strongly correlated with presence of psychosis (OR 1.068 (1.015-1.123)). Analysis showed that TGF- β can be a valuable marker for psychosis (area = 0.775, p < 0.0005). The optimal cutoff value estimated for TGF- β that allows the discrimination of psychotic from non psychotic patients was 22 pg/ml. For this cut-off we got sensitivity 70.4% and specificity 80.6%, i.e. this concentration of 22 pg/ml TGF- β could have prognostic value. We envisage the possible role of TGF- β as a biomarker in preceding schizophrenia and showed that increased level of TGF- β enhanced the risk for psychosis. According to our results, TGF- β could be a valuable marker for schizophrenia.
Role of cytokines has been widely investigated in schizophrenia. Previous data suggest that TGF- β pathways can be hyperactive in schizophrenia. Serum levels of TGF- β showed to be significantly increased in psychotic patients with first episode psychosis and schizophrenia in relapse. As a part of recently publish research, we try to establish if TGF- β can be a valuable marker for psychosis. We investigated psychotic patients, with first episode psychosis and schizophrenia in relapse (133 subjects) and healthy controls (36 subjects). Diagnoses were established using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). The psychopathological status of psychotic patients was assessed by trained physicians using Positive and Negative Syndrome Scale (PANSS). Serum level of cytokine was measured using sensitive enzyme-linked immunosorbent assay (ELISA). Binary logistic regression showed that increased level of TGF- β strongly correlated with presence of psychosis (OR 1.068 (1.015-1.123)). Analysis showed that TGF- β can be a valuable marker for psychosis (area=0.775, p<0.0005). The optimal cutoff value estimated for TGF- β that allows the discrimination of psychotic from non psychotic patients was 22pg/ml. For this cut-off we got sensitivity 70.4% and specificity 80.6%, i.e. this concentration of 22pg/ml TGF- β could have prognostic value. We envisage the possible role of TGF- β as a biomarker in preceding schizophrenia and showed that increased level of TGF- β enhanced the risk for psychosis. According to our results, TGF- β could be a valuable marker for schizophrenia.
ArticleNumber 28-E1248
Author Radosavljevic, G.
Stefanovic, V.
Lukic, M.L.
Djukic Dejanovic, S.
Jovanovic, I.
Arsenijevic, N.
Borovcanin, M.
Author_xml – sequence: 1
  givenname: M.
  surname: Borovcanin
  fullname: Borovcanin, M.
  organization: Department of Psychiatry
– sequence: 2
  givenname: S.
  surname: Djukic Dejanovic
  fullname: Djukic Dejanovic, S.
  organization: Department of Psychiatry
– sequence: 3
  givenname: G.
  surname: Radosavljevic
  fullname: Radosavljevic, G.
  organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac
– sequence: 4
  givenname: I.
  surname: Jovanovic
  fullname: Jovanovic, I.
  organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac
– sequence: 5
  givenname: V.
  surname: Stefanovic
  fullname: Stefanovic, V.
  organization: Clinic for Mental Disorders ‘Dr Laza Lazarevic’, Belgrade, Serbia
– sequence: 6
  givenname: N.
  surname: Arsenijevic
  fullname: Arsenijevic, N.
  organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac
– sequence: 7
  givenname: M.L.
  surname: Lukic
  fullname: Lukic, M.L.
  organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac
BookMark eNqNkE1KAzEUgINUsK0eQchSF6P5mUwyiBYptgoFF9Z1SDNvMO04U5K20J138CYexEN4EmdacVGQunqb932873VQq6xKQOiUkgtKaHL5RFIWRynn6ozyc5mkCYnUAWpTKVXEhRIt1P5dOUKdEKaEUElI0kaKEU7w19s77psSj4eDCH9-4Algg1emWJpJAfjV-Bl4nFcez8PavlTBhd4xOsxNEeDkZ3bR8-Bu3L-PRo_Dh_7tKLIs4SpSWcZ5TJgEoLFVkkmeigziOAMuRZwbIYBRJUWujIwBpFApU8QokrEktSnvIrH1Wl-F4CHXc-_qi9aaEt3k602-bto05XqTr1XNXe1w1i3MwlXlwhtX7KV7WxrqtJUDr4N1UFrInAe70Fnl9hpudgy2cKWzppjBGsK0Wvqy_pumOjBNtpLGQfnG0Aiu_xb844BvHqOcPQ
CitedBy_id crossref_primary_10_1038_s41598_024_73937_0
ContentType Journal Article
Copyright 2013 Elsevier Masson SAS
Elsevier Masson SAS
Copyright_xml – notice: 2013 Elsevier Masson SAS
– notice: Elsevier Masson SAS
DBID AAYXX
CITATION
DOI 10.1016/S0924-9338(13)76960-8
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList


CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1778-3585
EndPage 1
ExternalDocumentID 10_1016_S0924_9338_13_76960_8
S0924933813769608
1_s2_0_S0924933813769608
GroupedDBID ---
--K
--M
.1-
.FO
.~1
09C
09E
0R~
1B1
1P~
1~.
1~5
29G
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8FI
8FJ
8P~
AABNK
AAEDT
AAEDW
AAFWJ
AAIKJ
AAKOC
AALRI
AANRG
AAOAW
AAQXK
AASVR
AAXMD
AAXUO
AAYWO
ABBQC
ABBZL
ABFNM
ABGDZ
ABIVO
ABJNI
ABMZM
ABUWG
ABVKB
ABWVN
ABXAU
ABXDB
ABXHF
ACAJB
ACDAQ
ACDLN
ACGFS
ACHQT
ACIUM
ACQPF
ACRPL
ACVFH
ACZWT
ADAZD
ADBBV
ADCNI
ADDNB
ADEZE
ADKIL
ADMUD
ADNMO
ADOVH
ADVJH
ADVLN
AEBAK
AEKER
AENCP
AENEX
AEUPX
AEVXI
AEYHU
AFKRA
AFPKN
AFPUW
AFRHN
AFTJW
AFZFC
AGABE
AGHFR
AGJUD
AGQPQ
AGUBO
AGYEJ
AHIPN
AHRGI
AIGII
AITUG
AJPFC
AJRQY
AJUYK
AKBMS
AKMAY
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANZVX
AQJOH
ASPBG
AVWKF
AZFZN
AZQEC
BENPR
BLXMC
BLZWO
CCPQU
CCQAD
CCUQV
CFBFF
CGQII
CJCSC
CS3
DOHLZ
DU5
DWQXO
EBS
EGQIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYUFA
G-Q
GBLVA
GNUQQ
GROUPED_DOAJ
HVGLF
HZ~
IHE
IKXGN
IOO
IPYYG
J1W
LN9
M2M
M41
MO0
N9A
NZEOI
O-L
O9-
OAUVE
OH0
OK1
OU-
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PIMPY
PSYQQ
PUEGO
Q38
R2-
RCA
ROL
RPM
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SSZ
UHS
UKHRP
UV1
WFFJZ
Z5R
~G-
0SF
AACTN
AFCTW
AJOXV
ALIPV
AMFUW
NCXOZ
RIG
T5K
AAEED
AAQFI
ABYKQ
AEBPU
AJBFU
EFLBG
LCYCR
LW7
AAYXX
CITATION
ID FETCH-LOGICAL-c2638-8dd334027ee14c8727395de44de3754fa55e21875f8a74ee7589280a80d269c93
IEDL.DBID .~1
ISSN 0924-9338
IngestDate Thu Apr 24 22:51:53 EDT 2025
Tue Jul 01 05:33:28 EDT 2025
Fri Feb 23 02:25:06 EST 2024
Sun Feb 23 10:19:43 EST 2025
Tue Aug 26 16:31:41 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue S1
Language English
License https://www.cambridge.org/core/terms
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2638-8dd334027ee14c8727395de44de3754fa55e21875f8a74ee7589280a80d269c93
PageCount 1
ParticipantIDs crossref_primary_10_1016_S0924_9338_13_76960_8
crossref_citationtrail_10_1016_S0924_9338_13_76960_8
elsevier_sciencedirect_doi_10_1016_S0924_9338_13_76960_8
elsevier_clinicalkeyesjournals_1_s2_0_S0924933813769608
elsevier_clinicalkey_doi_10_1016_S0924_9338_13_76960_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013
2013-00-00
PublicationDateYYYYMMDD 2013-01-01
PublicationDate_xml – year: 2013
  text: 2013
PublicationDecade 2010
PublicationTitle European psychiatry
PublicationYear 2013
Publisher Elsevier SAS
Publisher_xml – name: Elsevier SAS
SSID ssj0017006
Score 1.9880133
Snippet Role of cytokines has been widely investigated in schizophrenia. Previous data suggest that TGF- β pathways can be hyperactive in schizophrenia. Serum levels...
SourceID crossref
elsevier
SourceType Enrichment Source
Index Database
Publisher
StartPage 1
SubjectTerms Internal Medicine
Psychiatry
Title 2030 – Can TGF- β be a valuable marker for psychosis?
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0924933813769608
https://www.clinicalkey.es/playcontent/1-s2.0-S0924933813769608
https://dx.doi.org/10.1016/S0924-9338(13)76960-8
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1778-3585
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017006
  issn: 0924-9338
  databaseCode: DOA
  dateStart: 19910101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1778-3585
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017006
  issn: 0924-9338
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1778-3585
  dateEnd: 20191001
  omitProxy: true
  ssIdentifier: ssj0017006
  issn: 0924-9338
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NS8MwGA5jB_EifuL8GDl40EO2Nk3b9CQynEOYFzfYLbRJCoM5xzqv4n_wn_hD_BH-Et-k6aY4GHgNedPy8H4m7wdCF4mWlEVhTmROGWHai0kWZ4wkYagVTRnEY6beuf8Q9YbsfhSOaqhT1cKYtEqn-0udbrW1W2k7NNuz8bj96JnQASIsH2QE_HBT8Gu6fwFPt16XaR6m_Zx9r4TNxOxeVfGUJ9jFSz-4socQvt4-_bA53V2045xFfFP-zx6q6ek-2uq75_ADBHY18PDX2zvupFM8uOsS_PmBM41TbJt4ZxONn0z-zRyDb4rLiqtiXFwfomH3dtDpETcKgUgKEkK4UkEAoV6stc8kN05HEirNmNJmhm2eArRgrOMw52nMtIYoIKHcS7mnaJTIJDhC9enzVB8jHEuZZHmQspQnjNI44ypkkpku3UCrggZiFQBCuj7hZlzFRKwSwgA3YXATfiAsboI3UGtJNisbZWwiiCp0RVUFCnpLgCrfRBivI9SFk75C-KKgwhN_OKSB-JLyF5Nt_ujJ_0lP0Ta1MzTMvc0Zqi_mL_ocPJlF1rSs2rT3AN_i6-dE
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LTsJAFL1BTNSN8RnxOQsXuhhop1M6XRlDRFRgIyTsJu10mpAgEopb4z_4J36IH-GXeKctoJGExO1kzrQ5uXMf7X0AnPtaMV51Y6pixinXlkdDL-TUd10dsYBjPGbqnVvtaqPL73turwC1aS2MSavMdX-m01Ntna9UcjYro36_8miZ0AEjLBvvCPrhYgVWuZEoFOry6yzPw_SfS39Y4m5qts_LeLIj0sUL27lMT6FisYH6YXTqW7CZe4vkOnuhbSjo4Q6stfL_4buAhtWxyNfbO6kFQ9K5rVPy-UFCTQKSdvEOB5o8mQScMUHnlGQlV0k_udqDbv2mU2vQfBYCVQyvCBVR5DgY63la21wJ43X4bqQ5j7QZYhsHyC1aa8-NReBxrTEM8JmwAmFFrOor39mH4vB5qA-AeEr5YewEPBA-Z8wLReRyxU2bbsRGTgn4lACp8kbhZl7FQM4zwpA3aXiTtiNT3qQoQXkGG2WdMpYBqlN25bQMFBWXRF2-DOgtAuokv36JtGXCpCX_iEgJxAz5S8qWP_Tw_9AzWG90Wk3ZvGs_HMEGSwdqmI84x1CcjF_0Cbo1k_A0FdtvGp3pbQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=2030+%E2%80%93+Can+TGF-+%CE%B2+be+a+valuable+marker+for+psychosis%3F&rft.jtitle=European+psychiatry&rft.au=Borovcanin%2C+M.&rft.au=Djukic+Dejanovic%2C+S.&rft.au=Radosavljevic%2C+G.&rft.au=Jovanovic%2C+I.&rft.date=2013&rft.pub=Elsevier+SAS&rft.issn=0924-9338&rft.volume=28&rft.spage=1&rft.epage=1&rft_id=info:doi/10.1016%2FS0924-9338%2813%2976960-8&rft.externalDocID=S0924933813769608
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09249338%2FS0924933813X70142%2Fcov150h.gif